Neuroblasztóma: vizsgálatok itt: Németország
10 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 2/3. fázisTaking peopleA Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients
- Where
- Berlin
- Életkor
- 18 hónap to 18 év
- People
- 144 worldwide
- Run by
- Renaissance Pharma Ltd.
See details and how to joinNCT07549321 · EU 2025-524397-42-00 - 1. fázisNot yet taking people in NémetországGD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors
- Where
- Münster
- Életkor
- 1 év to 25 év
- People
- 30
- Run by
- Universität Münster
See details and how to joinNCT07897968 - 1/2. fázisTaking peopleSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Where
- Berlin, Cologne, Giessen, Muenster, Tuebingen
- Életkor
- 6 hónap to 25 év
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00 - 3. fázisNot yet taking people in NémetországProspective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR
- Where
- Aachen, Augsburg, Berlin, Bielefeld, Bonn, Bremen, Cologne, Dortmund, Dresden, Erfurt, Erlangen, Giessen, Goettingen, Halle (Saale), Jena, Karlsruhe, Kassel, Krefeld, Leipzig, Magdeburg, Mainz, Mannheim, Muenster, Regensburg, Sankt Augustin, Stuttgart, Wuerzburg
- Életkor
- Up to 64 év
- People
- 231
- Run by
- University Of Cologne
See details and how to join2024-517295-37-00 · EU 2024-517295-37-00 - 1. fázisTaking peopleLong-term follow-up of patients treated with GD2IL18CART
- Where
- Erlangen, Essen, Muenster, Tuebingen
- People
- 20
- Run by
- Universitaet Muenster
See details and how to join2025-521497-34-00 · EU 2025-521497-34-00 - 1. fázisTaking peopleA phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers
- Where
- Erlangen, Essen, Muenster, Tuebingen
- People
- 48
- Run by
- Universitaet Muenster
See details and how to join2022-501725-21-00 · EU 2022-501725-21-00 - 1/2. fázisTaking peopleA phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies
- Where
- Berlin, Essen, Frankfurt Am Main, Hamburg, Muenster
- Életkor
- Up to 64 év
- People
- 72 worldwide
- Run by
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
See details and how to join2023-504880-18-00 · EU 2023-504880-18-00 - 1/2. fázisTaking peopleA Multi-Arm, Platform Trial For Relapsed Neuroblastoma
- Where
- Augsburg, Berlin, Essen, Greifswald, Hamburg, Köln, Mainz, München, Münster, Regensburg, Tübingen
- Életkor
- 1 év to 64 év
- People
- 160 worldwide
- Run by
- University of Birmingham
See details and how to joinNCT07334301 · EU 2024-516115-24-00 - 1. fázisTaking peopleStudy Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma
- Where
- Berlin, Cologne, Greifswald, Tuebingen
- Életkor
- 18 hónap to 18 év
- People
- 38 worldwide
- Run by
- Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT06485947 · EU 2023-509673-22-00 - 3. fázisTaking peopleHigh-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
- Where
- Aachen, Augsburg, Berlin, Bielefeld, Bonn, Bremen, Dortmund, Dresden, Düsseldorf, Erfurt, Erlangen, Essen, Frankfurt, Giessen, Göttingen, Greifswald, Halle Saale, Hamburg, Hanover, Heidelberg, Homburg, Jena, Karlsruhe, Kassel, Kiel, Köln, Krefeld, Leipzig, Luebeck, Magdeburg, Mainz, München, Münster, Regensburg, Rostock, Stuttgart, Tübingen, Ulm, Würzburg, UNIVERSITÄTSKLINIKUM FREIBURG
- Életkor
- Up to 21 év
- People
- 800 worldwide
- Run by
- Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT04221035 · EU 2024-514917-36-00